Cargando…

The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis

OBJECTIVE: To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). METHODS: Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies until August 10, 2021. The data on overall s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chunmei, Zhao, Wancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396859/ https://www.ncbi.nlm.nih.gov/pubmed/35996165 http://dx.doi.org/10.1186/s13048-022-01028-7

Ejemplares similares

Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Simion, Laurentiu, et al.
Publicado: (2023)

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
por: Yu, Jing, et al.
Publicado: (2016)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer
por: Lin, Heng, et al.
Publicado: (2016)

Surgery in Recurrent Ovarian Cancer: A Meta-Analysis
por: Climent, Maria Teresa, et al.
Publicado: (2023)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
por: Yang, Yingzhu, et al.
Publicado: (2020)

The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yaping, et al.
Publicado: (2023)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
por: Zeng, Siyuan, et al.
Publicado: (2023)

Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis
por: Yang, Lili, et al.
Publicado: (2017)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wang, Haihong, et al.
Publicado: (2018)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
por: Shao, Fengping, et al.
Publicado: (2020)

Circ‐PGAM1 promotes malignant progression of epithelial ovarian cancer through regulation of the miR‐542‐3p/CDC5L/PEAK1 pathway
por: Zhang, Chunmei, et al.
Publicado: (2020)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
por: Sun, Ximu, et al.
Publicado: (2021)

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis
por: Pei, Yaping, et al.
Publicado: (2021)

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review
por: Wang, Yawei, et al.
Publicado: (2016)

Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
por: Gavalas, Nikos G., et al.
Publicado: (2013)

Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis
por: Veettil, Sajesh K, et al.
Publicado: (2019)

Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials
por: Tong, Mengting, et al.
Publicado: (2019)

The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis
por: Li, Jun, et al.
Publicado: (2015)

Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis
por: Chen, Zhichao, et al.
Publicado: (2022)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
por: Wu, Kongju, et al.
Publicado: (2019)

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
por: Peng, Min, et al.
Publicado: (2018)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis
por: Elmoursi, Ahmed, et al.
Publicado: (2023)

Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis
por: Wang, Yuxuan, et al.
Publicado: (2020)

A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn's Disease
por: Huang, He, et al.
Publicado: (2018)

Angiogenesis inhibitors in the treatment of prostate cancer
por: Hwang, Clara, et al.
Publicado: (2010)

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis
por: Luo, Jing, et al.
Publicado: (2022)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis
por: Liu, Yi, et al.
Publicado: (2019)

Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis
por: Chen, Hui, et al.
Publicado: (2021)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
por: Zhao, Heng-Nan, et al.
Publicado: (2021)

Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis
por: Hu, Yunzhen, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis
por: Dong, Huijing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vdb9608pi76mdrvmm95ghpnunj